Key Highlights

  • Poolbeg dosed the first patient in its TOPICAL trial of POLB 001, evaluating prevention of cytokine release syndrome across six NHS sites.
  • Interim data are expected in late summer 2026, given CRS typically manifests within days to weeks of treatment.
  • The company estimates the addressable market at more than $10 billion in relapsed/refractory multiple myeloma and lymphoma alone.
  • POLB 001 has secured FDA Orphan Drug Designation and Patent protection through at least 2044.
  • A July 2026 conditional placing aims to raise £3.5 million, extending the funding runway toward Q2 2028.

LSE-listed Poolbeg Pharma has dosed its first patient in a six-site NHS trial of POLB 001, an oral drug designed to prevent cytokine release syndrome in cancer immunotherapy. The company puts the addressable market above $10 billion, with interim data due this summer.

Poolbeg Pharma (LSE:POLB), the LSE-listed clinical-stage biopharmaceutical company, has reached what its chief executive calls a "transformative" moment. In July 2026 it dosed the first patient in a UK-wide NHS trial of POLB 001, its lead candidate designed to prevent a dangerous inflammatory reaction linked to cancer immunotherapies. For a small-cap that has weathered a collapsed Merger and years of losses, this is a real test of whether its pipeline can translate into commercial value.

What Happened

On 13 July 2026, Poolbeg (LSE:POLB) confirmed via an RNS announcement that it had dosed the first patient in its TOPICAL trial, evaluating POLB 001 as a preventative treatment for cytokine release syndrome (CRS). The trial runs across six NHS hospital sites, enrolling around 30 patients with relapsed or refractory multiple myeloma. Participants receive Johnson & Johnson's bispecific antibody Tecvayli (teclistamab) alongside POLB 001, testing whether the oral drug reduces CRS, a life-threatening cytokine surge that can follow CAR-T and bispecific antibody immunotherapies.

The dosing followed an MHRA Clinical Trial Authorisation in April 2026 and site activation in June. Poolbeg expects interim data in late summer 2026, noting CRS typically manifests within days to weeks of treatment, so results could emerge quickly. It also follows a string of IP wins in 2025-26, with patents granted for POLB 001 in CRS in South Korea, Europe (twice), Canada and South Africa, plus a Notice of Allowance in Israel; the patent estate provides protection through at least 2044.

Why It Matters

Cytokine release syndrome is a principal safety hurdle limiting wider use of CAR-T cell therapies and bispecific antibodies in cancer treatment. It can restrict these therapies to specialist centres equipped to manage the toxicity and, in severe cases, requires intensive care. A drug that reliably prevents or blunts CRS could allow immunotherapies to be given more widely, including in community hospitals, and ease the monitoring burden that makes them costly.

For Poolbeg, POLB 001 is by far its most advanced and closely watched asset. The molecule, an oral p38 MAPK inhibitor licensed from Spanish company Palau Pharma, has already secured FDA Orphan Drug Designation. Positive interim data from TOPICAL would be the clearest evidence yet that the approach works in patients, rather than in the animal models and mechanistic studies underpinning the programme so far.

Latest Financial and Operational Performance

Poolbeg's results for the year to 31 December 2025, published on 28 April 2026, showed cash of £7.7 million at year end (2024: £7.8 million), a net loss of £5.7 million (2024: £5.8 million), an operating loss of £6.0 million (2024: £6.4 million) and R&D spend of £1.5 million (2024: £1.4 million). The company said this was funded through to 2027, based on delivery of near-term clinical milestones.

That position was supported by an oversubscribed June 2025 fundraise that raised £4.865 million gross at 2.5p per share. A further conditional placing to raise £3.5 million, announced on 14 July 2026 and advised on by DAC Beachcroft, was intended to fund two Clinical Trials to completion and strengthen the company's hand in partnering talks; investor materials subsequently referenced funding extending to Q2 2028. As at February 2026, following option exercises, 705,103,778 ordinary shares were in issue.

Beyond POLB 001, Poolbeg's other clinical-stage asset is an oral, encapsulated GLP-1 programme for obesity; a proof-of-concept trial was expected in the second half of 2026. It also holds earlier-stage, AI-assisted discovery programmes in RSV and influenza, for which it continues to seek partnering deals.

Key Numbers

  • Cash at 31 December 2025: £7.7 million
  • Net loss for FY2025: £5.7 million
  • Operating loss for FY2025: £6.0 million
  • R&D spend FY2025: £1.5 million
  • June 2025 fundraise: £4.865 million gross at 2.5p per share
  • July 2026 conditional placing: £3.5 million
  • Ordinary shares in issue (February 2026): 705,103,778
  • Estimated addressable market for POLB 001 in relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma: more than US$10 billion, per company disclosure

Growth Opportunities

The immediate opportunity is data-driven: positive interim TOPICAL results this summer would be a binary catalyst, potentially validating POLB 001's mechanism in humans and strengthening Poolbeg's hand with larger pharmaceutical partners, discussions it says it is already pursuing.

The scale of the opportunity, if the science holds up, is what draws investor attention. Poolbeg estimates the addressable market in relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma alone at more than US$10 billion, citing independent US pricing research pointing to multi-billion-dollar peak sales. As these therapies expand into earlier treatment lines and new indications, the population at risk of CRS — and the market for an effective preventative — could grow further.

The GLP-1 obesity programme offers a second, earlier-stage growth avenue in one of pharmaceuticals' fastest-growing categories, while the RSV and influenza discovery Assets offer potential out-licensing income that could supplement cash reserves without Poolbeg funding late-stage development itself.

Risks Investors Should Know

Poolbeg remains pre-revenue and loss-making, and its cash position depends on continued access to Capital Markets — the July 2026 placing being the latest dilutive fundraise. Clinical outcomes are inherently uncertain: a 30-patient interim readout, while informative, is a small dataset, and larger, later-stage trials would likely be needed before any commercial application. The company's history includes a proposed merger with HOOKIPA Biotech terminated in February 2025, a reminder that strategic plans here can change. Regulatory pathways for CRS-prevention drugs are still developing, and competing approaches to immunotherapy toxicity cannot be ruled out.

What to Watch Next

The near-term catalyst is interim TOPICAL data, expected late summer 2026. Investors will also watch progress on the GLP-1 proof-of-concept trial planned for the second half of the year, any licensing news on the RSV and influenza programmes, and confirmation that the £3.5 million placing has completed and extended the cash runway as intended.

Outlook

Poolbeg has moved from patent filings into the clinic, with patients now receiving POLB 001 across NHS sites. That is a meaningful step for a company whose value rests heavily on one lead asset and a market opportunity it measures in the billions of dollars. Whether that promise converts into Shareholder value depends on what the TOPICAL data show this summer, and on the company's ability to keep funding its ambitions meanwhile.